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TFAP2E-DKK4 and Chemoresistance in Colorectal Cancer
To the Editor: Ebert et al. (Jan. 5 issue)1 report 
that hypermethylation of the gene encoding tran-
scription factor AP-2 epsilon (TFAP2E) reduces 
its expression and is associated with chemoresis-
tance in patients with colorectal cancer and in 
colorectal-cancer cell lines in vitro.
The test has dramatic clinical value: the re-
sponse rate increased from less than 15% among 
hypomethylated tumors to more than 80% 
among hypermethylated tumors. Methylation of 
this gene had a huge biologic and clinical effect.
However, we have several questions. First, the 
methylation status differs between primary tu-
mors and metastases in approximately 30% of 
tumors: were these tumors considered to be 
hypermethylated or not?
Second, the design of in vitro tests is not 
consistent with clinical data: patients were treat-
ed with drug combinations or chemoradiation, 
and cells were exposed to single drugs.
The antiproliferative activity reported was 
limited, even if drug concentrations for irinotecan 
(20 μM), oxaliplatin (60 μM), and fluorouracil 
(382 μM) were very high and not comparable to 
clinical data.2,3 Concerning the evaluation of 
methylation in vitro, drug combinations might 
confound the effects,4 and it is unclear whether 
azacytidine or aza-2-deoxycytidine was used.
Finally, in vitro data show increased resis-
tance only to fluorouracil, whereas clinical data 
suggest that alterations of TFAP2E–DKK4 could 
represent a more global chemotherapy-resistance 
marker.
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The Authors Reply: We are fully aware of the 
shortcomings and limitations of our study. Since 
most patients with colorectal cancer underwent 
combination therapy, we were not able to address 
the role of TFAP2E in fluorouracil monotherapy. 
Thus, based on our findings, we concluded that 
TFAP2E may present a more global resistance 
marker. For the in vitro studies, different agents, 
including azacytidine, were used; the role of drug 
combinations in the predictive value of TFAP2E 
was not addressed in our study. We agree that the 
methylation status differs in a subgroup of pri-
mary and metastatic lesions; however, no re-
sponse data on the patient cohorts that were 
used to assess methylation in primary and meta-
static lesions were available. We believe that our 
observations need to be prospectively evaluated 
in a clinical trial. So far, our study is a retrospec-
tive analysis with evidence from in vitro experi-
ments that may indicate a role of TFAP2E in pre-
dicting treatment response.
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